Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,374.00+0.30%ETH$2,445.61+1.12%GOLD$4,383.30-0.37%OIL$101.10-0.79%
Smart Investors Daily
Vivos Inc. logo

OTC · RDGL

Vivos Inc.

Healthcare · Medical - Devices

$0.05

Up+$0.00 (+2.71%)

Updated Sep 17, 2026, 11:45 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
30.69M
P/E ratio
-9.2
Dividend yield
0.00%
52-week range
— – —
Volume
486.6K
Avg. volume
885.23K

Price performance

RDGL price history

1M range · 0 trading sessions · Daily adjusted prices

RDGL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RDGL news

The latest Smart Investors Daily articles mentioning RDGL.

Stock researchCompany · Overview

RDGL research

Overview

Company profile and research snapshot.

Company profile

VIVOS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Vivos Therapeutics Announces Material Debt Reduction

Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing RequirementsLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced t

Yahoo · Sep 3, 2026

Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology

Kennewick, WA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company developing Precision Radionuclide Therapy™ (PRnT) for cancerous tumors in humans and animals, today announced the peer-reviewed publication of a paper describing the PrecisionGel™ thermogel polymer platform in the Journal of Drug Delivery Science and Technology. PrecisionGel™ is the polymer carrier component of both IsoPet® and RadioGel® and is also available independently to pharmaceutical and b

Yahoo · Sep 1, 2026

Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference

Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, taking place September 9...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By